Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/171332
Title: | Expression and Role of MicroRNAs from the miR-200 Family in the Tumor Formation and Metastatic Propensity of Pancreatic Cancer |
Author: | Diaz Riascos, Zamira Vanessa Ginestà, Mireia M. Fabregat Prous, Joan Serrano Piñol, M. Teresa Busquets Barenys, Juli Buscail, Louis Cordelier, Pierre Capellá, G. (Gabriel) |
Keywords: | Càncer de pàncrees Metàstasi Micro RNAs Pancreas cancer Metastasis MicroRNAs |
Issue Date: | 6-Sep-2019 |
Publisher: | Elsevier |
Abstract: | MicroRNAs from the miR-200 family are commonly associated with the inhibition of the metastatic potential of cancer cells, following inhibition of ZEB transcription factors expression and epithelial-to-mesenchymal transition. However, previous studies performed in pancreatic adenocarcinoma revealed a more complex picture challenging this canonical model. To gain better insights into the role of miR-200 family members in this disease, we analyzed the expression of miR-200a, miR- 200b, miR-200c, miR-141, miR-429, and miR-205, and ZEB1, ZEB2, and CDH1 in pancreatic tumors and matching normal adjacent parenchyma and patient-derived xenografts. We found that miR-200a, miR-429, and miR-205 are frequently overex- pressed in pancreatic tumors, whereas CDH1 is downregulated, and ZEB1 and ZEB2 levels remain unchanged. Furthermore, we measured a positive correlation between miR-200 family mem- bers and CDH1 expression, and a negative correlation between ZEB1 and miR-200c, miR-141, and miR-205 expression, respec- tively. Interestingly, we identified significant changes in expres- sion of epithelial-to-mesenchymal transition regulators and miR-200 members in patient-derived xenografts. Lastly, func- tional studies revealed that miR-141 and miR-429 inhibit the tumorigenic potential of pancreatic cancer cells. Taken together, this comprehensive analysis strongly suggests that miRNAs from the miR-200 family, and in particular miR-429, may act as a tu- mor suppressor gene in pancreatic cancer. |
Note: | Reproducció del document publicat a: https://doi.org/10.1016/j.omtn.2019.06.015 |
It is part of: | Molecular Therapy-Nucleic Acids, 2019, vol. 17, p. 491-503 |
URI: | http://hdl.handle.net/2445/171332 |
Related resource: | https://doi.org/10.1016/j.omtn.2019.06.015 |
ISSN: | 2162-2531 |
Appears in Collections: | Articles publicats en revistes (Patologia i Terapèutica Experimental) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
703504.pdf | 3.37 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License